ipilimumab
Sign in to saveAlso known as MDX-010, MDX-101, MOAB-CTLA-4, MDX-CTLA-4
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Research
7,201 papers- Improved survival with ipilimumab in patients with metastatic melanoma.The New England journal of medicine · 2010
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.The New England journal of medicine · 2019
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.The New England journal of medicine · 2017
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.The Lancet. Oncology · 2018
- The foundations of immune checkpoint blockade and the ipilimumab approval decennial.Nature reviews. Drug discovery · 2022
via PubMed
Wikidata facts
Show 1 more fact
- World Health Organisation international non-proprietary name
- ipilimumab
Sources (6)
via Wikidata · CC0
~13 min read
Article
15 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Mechanism of action
- Pharmacokinetics
- History
- Clinical trial history
- Melanoma
- Prostate cancer
- Lung cancer
- Urothelial cancer, including cancer of the bladder, urethra, ureters and renal pelvis
- Combination trials
- Advanced melanoma
- References
- External links
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and boosts the body's immune response against cancer cells.
Connections
The New York Times
Entity
prostate cancer
Entity
monoclonal antibody
Entity
biological half-life
Entity
androgen receptor
Protein
fusion protein
Entity
dinutuximab
Entity
lumiliximab
Entity
human
Entity
International Standard Book Number
Entity
immunity
Entity
public domain
Entity
digital object identifier
Entity
leukemia
Entity
chemical formula
Entity
International Standard Serial Number
Entity
Nobel Prize in Physiology or Medicine
Entity
University of California, Berkeley
Entity
lymphatic system
Entity
molar mass
Entity
Categories
Chemicals that do not have a ChemSpider ID assignedDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by Bristol Myers SquibbDrugs that are a monoclonal antibodyDrugs with non-standard legal statusMonoclonal antibodies for tumorsSource attribution